摘要
Abstract
Non-alcoholic steatohepatitis(NASH),also known as metabolic steatohepatitis,is a clinical syndrome with pathological changes similar to alcoholic hepatitis but without history of excessive drinking,likely to occur in the middle-aged,especially overweight and obese individuals.Nonalcoholic steatohepatitis is closely related to obesity,insulin resistance,type 2 diabetes,hyperlipidemia and other metabolic disorders.Its main feature is hepatocyte vesicular steatosis with hepatocyte injury and inflammation.Severe cases can develop into liver cirrhosis,but so far there is no approved treatment for NASH.In the search for effective treatments,new strategies to address metabolic disorders,inflammation and anti-fibrosis are constantly emerging.Besides being a key regulator of bile acid metabolism and enterohepatic circulation,farnesoid X receptor(FXR)is also involved in regulating metabolic homeostasis,making it an attractive therapeutic target in NASH.This article reviews the progress and prospect of FXR agonists in the treatment of NASH.关键词
非酒精性脂肪性肝炎/脂肪性肝病/代谢紊乱/法尼类X受体/FXR激动剂Key words
Non-alcoholic steatohepatitis/Fatty liver disease/Metabolic disorder/Farnesoid X receptor/Farnesoid X receptor agonist分类
医药卫生
